While inhibition of S1P5 is considered a prospective treatment for LGL12, antagonism of S1P1 leads to serious adverse effects such as lung capillary leakage, renal reperfusion injury, and cancer angiogenesis19. This evidence concerns the gene S1PR5 and cancer.